| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.00087 | 1 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.0006 | 1 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.00056 | 1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.00056 | 1 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0005 | 1 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.00038 | 1 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | -0.00042 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.00038 | 1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.00043 | 1 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.00032 | 1 |